Nantahala Capital Management LLC Sells 51,825 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Nantahala Capital Management LLC reduced its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 3.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,270,035 shares of the company’s stock after selling 51,825 shares during the quarter. Aura Biosciences accounts for approximately 0.6% of Nantahala Capital Management LLC’s holdings, making the stock its 29th biggest position. Nantahala Capital Management LLC owned about 2.56% of Aura Biosciences worth $9,601,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Matrix Capital Management Company LP raised its holdings in Aura Biosciences by 29.1% in the 4th quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock worth $61,337,000 after purchasing an additional 1,560,000 shares during the period. Long Focus Capital Management LLC boosted its position in shares of Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the period. Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after purchasing an additional 216,266 shares in the last quarter. Platinum Investment Management Ltd. bought a new stake in shares of Aura Biosciences during the 4th quarter valued at $1,596,000. Finally, Regency Capital Management Inc. DE lifted its stake in shares of Aura Biosciences by 11.4% during the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after buying an additional 80,162 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Stock Down 1.3 %

Aura Biosciences stock opened at $8.91 on Tuesday. The company’s 50-day moving average price is $8.71 and its 200-day moving average price is $7.91. The company has a market cap of $441.43 million, a PE ratio of -4.91 and a beta of 0.35. Aura Biosciences, Inc. has a twelve month low of $5.99 and a twelve month high of $12.35.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. As a group, sell-side analysts expect that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. JMP Securities boosted their price objective on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Aura Biosciences in a report on Friday, September 13th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Aura Biosciences has a consensus rating of “Buy” and an average target price of $21.67.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.